{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:17:28Z","timestamp":1792081048431,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z191100006619010"],"award-info":[{"award-number":["Z191100006619010"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802533"],"award-info":[{"award-number":["81802533"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2018YFA0902802"],"award-info":[{"award-number":["2018YFA0902802"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525700"],"award-info":[{"award-number":["2024ZD0525700"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The limited genomic data on non-muscle-invasive bladder cancer (NMIBC) hampers our understanding of its carcinogenesis and development. Specifically, Aristolochic acid (AA), a potent human carcinogenic compound from aristolochia plants and commonly found in Chinese herbal medicine, has been extensively documented as being closely associated with the onset and progression of bladder cancer. However, the field of AA-induced NMIBC remains largely unexplored in terms of its genomic and molecular characteristics, as well as clinical therapeutic strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To bridge this knowledge gap, we conducted a comprehensive study using a cohort of 81 NMIBC samples. We performed whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to obtain detailed genomic and transcriptomic data. We subjected these datasets to genomic analysis and subtype analysis to gain valuable insights into NMIBC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>By temporally dissecting mutations in NMIBC specimens, we identified a comprehensive mutational landscape of NMIBC and the associations of these mutations with recurrence-free survival. Additionally, we discerned four genomic subtypes of NMIBC: AA-like, FGFR3\/HRAS, FGFR3 &amp; chr9Del, and genome instability (GI). The AA-like subtype presented a high frequency of gene mutations along with a pronounced AA mutagenesis signature of SBS22 (Fisher test: P-value 3.5e-4, OR 25.25) even after temporal dissection. The FGFR3\/HRAS subtype exhibited FGFR3 or HRAS mutations with few copy number alterations (CNAs). The FGFR3 &amp; chr9Del subtype was characterized by the co-occurrence of chr9p and chr9q deletions as well as FGFR3 mutations, while the GI subtype showed a high frequency of CNAs. Notably, the AA-like and GI subtypes demonstrated better outcomes after immunotherapy, whereas the FGFR3\/HRAS subtype showed poorer outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings provide novel perspectives on the genomics of NMIBC, unveiling four prominent genomic subtypes, each showing different outcomes following immunotherapy.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic>: No. 2019PHB268-01 (retrospectively registered on February 14, 2020).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s10020-025-01199-1","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:50:41Z","timestamp":1744883441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid"],"prefix":"10.1186","volume":"31","author":[{"given":"Yun","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/0471142905.hg0720s76","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protocols Human Genetics. 2013. https:\/\/doi.org\/10.1002\/0471142905.hg0720s76.","journal-title":"Curr Protocols Human Genetics"},{"key":"1199_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, et al. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev. 2023. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102530.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1199_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"12","key":"1199_CR4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/ng.2799","volume":"45","author":"C Balb\u00e1s-Mart\u00ednez","year":"2013","unstructured":"Balb\u00e1s-Mart\u00ednez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, M\u00e1rquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45(12):1464\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"1199_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA: A Cancer J Clin"},{"issue":"7467","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338\u201345.","journal-title":"Nature"},{"issue":"7438","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature11935","volume":"494","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494(7438):492\u20136.","journal-title":"Nature"},{"issue":"1","key":"1199_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13059-016-1114-x","volume":"17","author":"S Canisius","year":"2016","unstructured":"Canisius S, Martens JWM, Wessels LFA. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 2016;17(1):261.","journal-title":"Genome Biol"},{"key":"1199_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. Jco Precis Oncol. 2017;1:1\u201316.","journal-title":"Jco Precis Oncol"},{"issue":"2","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152\u201365.","journal-title":"Cancer Cell"},{"issue":"12","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","volume":"26","author":"EA Cotillas","year":"2024","unstructured":"Cotillas EA, Bernardo C, Veerla S, Liedberg F, Sj\u00f6dahl G, Eriksson P. A versatile and upgraded version of the lundtax classification algorithm applied to independent cohorts. J Mol Diagn. 2024;26(12):1081\u2013101.","journal-title":"J Mol Diagn"},{"issue":"12","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"1","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;1(12):105\u201317.","journal-title":"EBioMedicine"},{"issue":"5","key":"1199_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"1199_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2159-8290.CD-13-0285","volume":"4","author":"SM Dewhurst","year":"2014","unstructured":"Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Gr\u00f6nroos E, Endesfelder D, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 2014;4(2):175\u201385.","journal-title":"Cancer Discov"},{"key":"1199_CR15","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39:D945\u201350.","journal-title":"Nucleic Acids Res"},{"issue":"7957","key":"1199_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616(7957):525\u201333.","journal-title":"Nature"},{"issue":"6","key":"1199_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell. 2021;39(6):793-809.e8.","journal-title":"Cancer Cell"},{"issue":"9","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ng.907","volume":"43","author":"Y Gui","year":"2011","unstructured":"Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43(9):875\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"1199_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 2013;14(1):7.","journal-title":"BMC Bioinform"},{"key":"1199_CR20","doi-asserted-by":"publisher","unstructured":"Harrell FE. Regression modeling strategies: With applications to linear models, logistic and ordinal regression, and survival analysis. Cham: Springer; 2015 (Springer Series in Statistics). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-319-19425-7","DOI":"10.1007\/978-3-319-19425-7"},{"issue":"7","key":"1199_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.urolonc.2018.10.015","volume":"40","author":"CD Hurst","year":"2022","unstructured":"Hurst CD, Knowles MA. Mutational landscape of non-muscle-invasive bladder cancer. Urol Oncol: Seminars Orig Investig. 2022;40(7):295\u2013303.","journal-title":"Urol Oncol: Seminars Orig Investig"},{"issue":"21","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","volume":"18","author":"CD Hurst","year":"2012","unstructured":"Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res. 2012;18(21):5865\u201377.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1199_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE, et al. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell. 2017;32(5):701-715.e7.","journal-title":"Cancer Cell"},{"issue":"22","key":"1199_CR24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non\u2013small-cell lung cancer. New Engl J Med. 2017;376(22):2109\u201321.","journal-title":"New Engl J Med"},{"issue":"2","key":"1199_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ucl.2013.01.004","volume":"40","author":"AC James","year":"2013","unstructured":"James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin N Am. 2013;40(2):261\u20139.","journal-title":"Urol Clin N Am"},{"issue":"5","key":"1199_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat AM, Li R, O\u2019Donnell MA, Black PC, Roupret M, Catto JW, et al. Predicting response to intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? a systematic. Rev Eur Urol. 2018;73(5):738\u201348.","journal-title":"Rev Eur Urol"},{"issue":"12","key":"1199_CR27","doi-asserted-by":"publisher","first-page":"204209862199772","DOI":"10.1177\/2042098621997727","volume":"1","author":"YC Kang","year":"2021","unstructured":"Kang YC, Chen MH, Lin CY, Lin CY, Chen YT. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies. Therapeutic Adv Drug Safety. 2021;1(12):2042098621997727.","journal-title":"Therapeutic Adv Drug Safety"},{"issue":"4","key":"1199_CR28","doi-asserted-by":"publisher","first-page":"a027060","DOI":"10.1101\/cshperspect.a027060","volume":"7","author":"DG Kent","year":"2017","unstructured":"Kent DG, Green AR. Order matters: the order of somatic mutations influences cancer evolution. Cold Spring Harb Perspect Med. 2017;7(4):a027060.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"1199_CR29","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","volume":"16","author":"YJ Kim","year":"2010","unstructured":"Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, et al. Gene signatures for the prediction of response to Bacillus Calmette-Gu\u00e9rin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res. 2010;16(7):2131\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1199_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","volume":"57","author":"GS Kulkarni","year":"2010","unstructured":"Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57(1):60\u201370.","journal-title":"Eur Urol"},{"issue":"7","key":"1199_CR31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u201381.","journal-title":"Nat Protoc"},{"issue":"7457","key":"1199_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"6512","key":"1199_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1126\/science.aba7300","volume":"370","author":"R Li","year":"2020","unstructured":"Li R, Du Y, Chen Z, Xu D, Lin T, Jin S, et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science. 2020;370(6512):82\u20139.","journal-title":"Science"},{"issue":"33","key":"1199_CR34","doi-asserted-by":"publisher","first-page":"S593","DOI":"10.1016\/j.annonc.2022.07.152","volume":"1","author":"J Li","year":"2022","unstructured":"Li J, Zhang Q, Tan Y, Duan Q, Sun T, Qi C. 120P The predictive value of LATS1 mutation for immune checkpoint inhibitors therapy in bladder cancer. Ann Oncol. 2022;1(33):S593.","journal-title":"Ann Oncol"},{"issue":"1","key":"1199_CR35","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12(1):2301.","journal-title":"Nat Commun"},{"key":"1199_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1\u201321. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"5","key":"1199_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029-1041.e21.","journal-title":"Cell"},{"key":"1199_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa1408","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Favero F, De Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aaa1408.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1199_CR39","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"2","key":"1199_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/BLC-211609","volume":"8","author":"K Meghani","year":"2022","unstructured":"Meghani K, Folgosa Cooley L, Piunti A, Meeks JJ. Role of chromatin modifying complexes and therapeutic opportunities in bladder cancer. Bladder Cancer. 2022;8(2):101\u201312.","journal-title":"Bladder Cancer"},{"key":"1199_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R. Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011. https:\/\/doi.org\/10.1186\/gb-2011-12-4-r41.","journal-title":"Genome Biol"},{"key":"1199_CR42","volume-title":"Wiley StatsRef: statistics reference online","author":"J Miles","year":"2014","unstructured":"Miles J. Tolerance and variance inflation factor. In: Wiley StatsRef: statistics reference online. Hoboken: Wiley; 2014."},{"issue":"5","key":"1199_CR43","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","volume":"7","author":"I Nordentoft","year":"2014","unstructured":"Nordentoft I, Lamy P, Birkenkamp-Demtr\u00f6der K, Shumansky K, Vang S, Hornsh\u00f8j H, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014;7(5):1649\u201363.","journal-title":"Cell Rep"},{"issue":"2","key":"1199_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","volume":"22","author":"M Olislagers","year":"2025","unstructured":"Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM. Molecular biomarkers of progression in non-muscle-invasive bladder cancer\u2014beyond conventional risk stratification. Nat Rev Urol. 2025;22(2):75\u201391.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1199_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"key":"1199_CR46","doi-asserted-by":"publisher","first-page":"e2300414","DOI":"10.1200\/PO.23.00414","volume":"8","author":"KM Pilala","year":"2024","unstructured":"Pilala KM, Kotronopoulos G, Levis P, Giagkos GC, Stravodimos K, Vassilacopoulou D, et al. MIR145 core promoter methylation in pretreatment cell-free DNA: a liquid biopsy tool for muscle-invasive bladder cancer treatment outcome. JCO Precis Oncol. 2024;8:e2300414.","journal-title":"JCO Precis Oncol"},{"key":"1199_CR47","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for statistical computing; 2020. Available from: https:\/\/www.R-project.org\/"},{"issue":"3","key":"1199_CR48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556.e25.","journal-title":"Cell"},{"key":"1199_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2014.00425","author":"MK Saadeldin","year":"2015","unstructured":"Saadeldin MK, Shawer H, Mostafa A, Kassem NM, Amleh A, Siam R. New genetic variants of LATS1 detected in urinary bladder and colon cancer. Front Genetics. 2015. https:\/\/doi.org\/10.3389\/fgene.2014.00425.","journal-title":"Front Genetics"},{"issue":"2","key":"1199_CR50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321-337.e10.","journal-title":"Cell"},{"issue":"8","key":"1199_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nmeth0810-575","volume":"7","author":"JM Schwarz","year":"2010","unstructured":"Schwarz JM, R\u00f6delsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575\u20136.","journal-title":"Nat Methods"},{"key":"1199_CR52","unstructured":"Sjoberg DD, Vertosick E. D curves: decision curve analysis for model evaluation. 2024 [cited 2025 Feb 14]. Available from: https:\/\/cran.r-project.org\/web\/packages\/dcurves\/index.html"},{"key":"1199_CR53","doi-asserted-by":"crossref","unstructured":"Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research. 2016. Available from: https:\/\/f1000research.com\/articles\/4-1521","DOI":"10.12688\/f1000research.7563.2"},{"issue":"2","key":"1199_CR54","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41592-020-01013-2","volume":"18","author":"M Tarabichi","year":"2021","unstructured":"Tarabichi M, Salcedo A, Deshwar AG, Ni Leathlobhair M, Wintersinger J, Wedge DC, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods. 2021;18(2):144\u201355.","journal-title":"Nat Methods"},{"issue":"476","key":"1199_CR55","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1198\/016214506000000302","volume":"101","author":"YW Teh","year":"2006","unstructured":"Teh YW, Jordan MI, Beal MJ, Blei DM. Hierarchical dirichlet processes. J Am Stat Assoc. 2006;101(476):1566\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1199_CR56","unstructured":"Therneau TM, Foundation M. A package for survival analysis in S. 2015. p. 83."},{"issue":"1","key":"1199_CR57","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.1038\/s41598-020-67850-5","volume":"10","author":"KE van der Vos","year":"2020","unstructured":"van der Vos KE, Vis DJ, Nevedomskaya E, Kim Y, Choi W, McConkey D, et al. Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer. Sci Rep. 2020;10(1):10952.","journal-title":"Sci Rep"},{"issue":"39","key":"1199_CR58","doi-asserted-by":"publisher","first-page":"16910","DOI":"10.1073\/pnas.1009843107","volume":"107","author":"P Van Loo","year":"2010","unstructured":"Van Loo P, Nordgard SH, Lingj\u00e6rde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci. 2010;107(39):16910\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1199_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565\u201374.","journal-title":"Med Decis Making"},{"issue":"7492","key":"1199_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"JN Weinstein","year":"2014","unstructured":"Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322.","journal-title":"Nature"},{"issue":"1","key":"1199_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41467-021-27792-6","volume":"13","author":"JKL Wong","year":"2022","unstructured":"Wong JKL, Aichm\u00fcller C, Schulze M, Hlevnjak M, Elgaafary S, Lichter P, et al. Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions. Nat Commun. 2022;13(1):178.","journal-title":"Nat Commun"},{"issue":"9","key":"1199_CR62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"XR Wu","year":"2005","unstructured":"Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1199_CR63","doi-asserted-by":"publisher","first-page":"739","DOI":"10.18632\/oncoscience.188","volume":"2","author":"XR Wu","year":"2015","unstructured":"Wu XR, Mendelsohn C, DeGraff DJ. Tumorigenicity of RTK\/RAS in urothelium. Oncoscience. 2015;2(9):739\u201340.","journal-title":"Oncoscience"},{"issue":"1","key":"1199_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther. 2023;8(1):1\u201338.","journal-title":"Sig Transduct Target Ther"},{"issue":"2014","key":"1199_CR65","first-page":"e569325","volume":"27","author":"HY Yang","year":"2014","unstructured":"Yang HY, Chen PC, Wang JD. Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference. Biomed Res Int. 2014;27(2014):e569325.","journal-title":"Biomed Res Int"},{"issue":"13","key":"1199_CR66","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3390\/ijms20133162","volume":"20","author":"HY Yang","year":"2019","unstructured":"Yang HY, Yang CC, Wu CY, Wang LJ, Lu KL. Aristolochic acid and immunotherapy for urothelial carcinoma: directions for unmet needs. Int J Mol Sci. 2019;20(13):3162.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1199_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nrg3317","volume":"13","author":"LR Yates","year":"2012","unstructured":"Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13(11):795\u2013806.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"1199_CR68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","volume":"21","author":"S Zhang","year":"2024","unstructured":"Zhang S, Lin T, Xiong X, Chen C, Tan P, Wei Q. Targeting histone modifiers in bladder cancer therapy\u2014preclinical and clinical evidence. Nat Rev Urol. 2024;21(8):495\u2013511.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1199_CR69","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"TCM Zuiverloon","year":"2012","unstructured":"Zuiverloon TCM, Nieuweboer AJM, V\u00e9kony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to Bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 2012;61(1):128\u201345.","journal-title":"Eur Urol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01199-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01199-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T11:04:13Z","timestamp":1744887853000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01199-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01199-1","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the Peking University People\u2019s Hospital approved this retrospective study, and a waiver of consent to participate was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}